FDA Approves Etcamah for ctDNA-Guided Switching
FDA granted accelerated approval to Etcamah (camizestrant) with continued CDK4/6 inhibition for adults with HR-positive, HER2-negative advanced breast cancer whose tumors develop an ESR1 mutation in circulating tumor DNA before radiographic progression on first-line…
